{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Castration-Resistant+Prostate+Cancer+%28CRPC%29&page=4", "query": { "condition": "Castration-Resistant Prostate Cancer (CRPC)", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 145, "total_pages": 15, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Castration-Resistant+Prostate+Cancer+%28CRPC%29&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Castration-Resistant+Prostate+Cancer+%28CRPC%29&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T19:07:06.724Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02903160", "title": "Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Abiraterone acetate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Radium-223 dichloride", "type": "DRUG" }, { "name": "cabazitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Icahn School of Medicine at Mount Sinai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 40, "start_date": "2017-01-13", "completion_date": "2021-11-15", "has_results": true, "last_update_posted_date": "2024-02-07", "last_synced_at": "2026-11-15T19:07:06.724Z", "location_count": 2, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02903160" }, { "nct_id": "NCT01199146", "title": "Abiraterone Post Ketoconazole for Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Abiraterone acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 42, "start_date": "2010-09-10", "completion_date": "2016-03-14", "has_results": true, "last_update_posted_date": "2018-01-08", "last_synced_at": "2026-11-15T19:07:06.724Z", "location_count": 2, "location_summary": "San Francisco, California • Chicago, Illinois", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01199146" }, { "nct_id": "NCT02384382", "title": "A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Carcinoma Metastatic to the Bone", "Castration Resistant Prostate Cancer" ], "interventions": [ { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 23, "start_date": "2015-11-30", "completion_date": "2019-05-03", "has_results": true, "last_update_posted_date": "2020-05-05", "last_synced_at": "2026-11-15T19:07:06.724Z", "location_count": 5, "location_summary": "Detroit, Michigan • Farmington Hills, Michigan • New Brunswick, New Jersey + 1 more", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "Farmington Hills", "state": "Michigan" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Madison", "state": "Wisconsin" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT02384382" }, { "nct_id": "NCT00560482", "title": "Efficacy Study of ABR-215050 to Treat Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "ABR-215050, tasquinimod", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Active Biotech AB", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 206, "start_date": "2007-12", "completion_date": "2015-08", "has_results": false, "last_update_posted_date": "2015-10-26", "last_synced_at": "2026-11-15T19:07:06.724Z", "location_count": 54, "location_summary": "Anchorage, Alaska • Anaheim, California • Baldwin Park, California + 43 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anaheim", "state": "California" }, { "city": "Baldwin Park", "state": "California" }, { "city": "Bellflower", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00560482" }, { "nct_id": "NCT01594918", "title": "Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "Cabazitaxel", "type": "DRUG" }, { "name": "Mitoxantrone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rahul Aggarwal", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 25, "start_date": "2012-06", "completion_date": "2017-06-23", "has_results": false, "last_update_posted_date": "2017-07-21", "last_synced_at": "2026-11-15T19:07:06.724Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • San Francisco, California • Nashville, Tennessee", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01594918" }, { "nct_id": "NCT01522443", "title": "Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Cancer", "Castration Resistant Prostate Cancer", "Pain", "Prostatic Neoplasms" ], "interventions": [ { "name": "cabozantinib", "type": "DRUG" }, { "name": "mitoxantrone", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 119, "start_date": "2012-03", "completion_date": "2015-01-13", "has_results": true, "last_update_posted_date": "2018-05-23", "last_synced_at": "2026-11-15T19:07:06.724Z", "location_count": 49, "location_summary": "Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 42 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Marina del Rey", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01522443" }, { "nct_id": "NCT01884285", "title": "AZD8186 First Time In Patient Ascending Dose Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Castrate-resistant Prostate Cancer CRPC", "Squamous Non-Small Cell Lung Cancer sqNSCLC", "Triple Negative Breast Cancer TNBC" ], "interventions": [ { "name": "Part A: AZD8186 monotherapy", "type": "DRUG" }, { "name": "Part B: AZD8186 monotherapy", "type": "DRUG" }, { "name": "Part C1: Abiraterone acetate combination with AZD8186", "type": "DRUG" }, { "name": "Part D1: AZD2014 combination with AZD8186", "type": "DRUG" }, { "name": "Part D2 AZD2014 combination with AZD8186", "type": "DRUG" }, { "name": "Part C2: Abiraterone acetate combination with AZD8186", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 147, "start_date": "2013-07-09", "completion_date": "2020-02-07", "has_results": false, "last_update_posted_date": "2020-05-29", "last_synced_at": "2026-11-15T19:07:06.724Z", "location_count": 5, "location_summary": "Boston, Massachusetts • Detroit, Michigan • New York, New York + 2 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Seattle", "state": "Washington" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01884285" }, { "nct_id": "NCT03569280", "title": "Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Castration-Resistant Prostate Cancer" ], "interventions": [ { "name": "Enzalutamide or Abiraterone or Apalutamid", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Kangpu Biopharmaceuticals, Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 16, "start_date": "2019-11-26", "completion_date": "2023-06-15", "has_results": false, "last_update_posted_date": "2023-07-18", "last_synced_at": "2026-11-15T19:07:06.724Z", "location_count": 3, "location_summary": "Las Vegas, Nevada • Port Jefferson Station, New York • Charlottesville, Virginia", "locations": [ { "city": "Las Vegas", "state": "Nevada" }, { "city": "Port Jefferson Station", "state": "New York" }, { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03569280" }, { "nct_id": "NCT01816048", "title": "NaF Positron Emission Tomography/Computed Tomography (PET/CT)Imaging to Assess Treatment Responsiveness to TAK-700 in Patients With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastasis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostatic Neoplasms", "Prostate Cancer" ], "interventions": [ { "name": "TAK-700", "type": "DRUG" }, { "name": "Fluorine F 18 Sodium Fluoride", "type": "RADIATION" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 8, "start_date": "2013-05", "completion_date": "2016-11", "has_results": true, "last_update_posted_date": "2019-12-09", "last_synced_at": "2026-11-15T19:07:06.724Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01816048" }, { "nct_id": "NCT01534052", "title": "A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Castration-Resistant Prostate Cancer (CRPC)" ], "interventions": [ { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 52, "start_date": "2011-10-21", "completion_date": "2017-04-18", "has_results": true, "last_update_posted_date": "2024-12-06", "last_synced_at": "2026-11-15T19:07:06.724Z", "location_count": 4, "location_summary": "Aurora, Colorado • Chicago, Illinois • Pittsburgh, Pennsylvania + 1 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01534052" } ] }